Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 7:45 PM
Ignite Modification Date: 2025-12-24 @ 7:45 PM
NCT ID: NCT05008003
Eligibility Criteria: Inclusion Criteria: * Patients must be 18 years of age or older, of either gender * Patients must be tested positive for SARS-CoV-2 by RT-PCR * Patients must exhibit typical symptoms of COVID-19 disease at screening such as fever, fatigue, a dry and contagious cough, loss of appetite, body aches, shortness of breath, mucus or phlegm, sore throat, headache, chills, sometimes withshaking, loss of smell or taste, congestion or runny nose, nausea, or vomiting, diarrhea, muscular pain etc. * Patients must be in the early stage of COVID-19 disease who do not require hospitalization at the time of screening * Patients must be under the care of a Physician for diagnosis of COVID-19 * Patients who have signed informed consent Exclusion Criteria: * Patients with proven hypersensitivity or allergic reaction to quercetin or curcumin * Patients with known chronic kidney disease with estimated creatinine clearance \< 50 mL/minute or need for dialysis * Patients who are severely hypotensive defined as needing hemodynamic pressors to maintain blood pressure * Patients taking anticoagulant/antiplatelet drugs such as Coumarine, Heparine, Aspirin, Clopidrogel, dalteparin, enoxaparin, ticlopidine and warparin. * Patients with gallstone obstruction * Hypothyroid suppering patients * Patients with moderate or severe thrombocytopenia (platelet count \<100 ×10⁹/L); * Pregnant patients
Healthy Volunteers: False
Sex: ALL
Minimum Age: 18 Years
Study: NCT05008003
Study Brief:
Protocol Section: NCT05008003